You can buy or sell ADVM and other stocks, options, ETFs, and crypto commission-free!
Adverum Biotechnologies, Inc. Common Stock, also called Adverum Biotechnologies, is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. Read More It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.
Menlo Park, California
52 Week High
52 Week Low
Seeking AlphaMay 24
Adverum Biotechnologies: A High Risk/High Reward Biotech Play In 2019
The recent lift of clinical hold on investigational ADVM-022 therapy by the FDA has reignited interest in Adverum Biotechnologies.
Seeking AlphaMay 20
Updated Investment Thesis On Adverum Biotechnologies
We take a look at that and other recent events as well as the first new analyst activity on the stock so far in 2019. The stock of Adverum Biotechnologies rose some 40% in trading this week, thanks to a lifting of an FDA hold on its primary drug candidate. Words rich in meaning can be cheap in sound effects." - Dejan Stojanovic Today, we revisit a 'Busted IPO' that has been 'en fuego' so far in 2019. The stock added some 40% to its recent gains this week even as the overall market sank. We will discuss r...
Adverum Biotechnologies Reports First Quarter 2019 Financial Results and Provides Corporate Update
MENLO PARK, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the first quarter ended March 31, 2019 and provided a corporate update. "Our primary focus is on advancing ADVM-022, our novel gene therapy designed as a single-administration treatment for wet AMD," said Leone Patterson, chief executive officer of Adverum Biotechnologies....
Expected Aug 7, After Hours